Ai Pathology raises R$4M seed to scale AI skin cancer screening in Brazil
What's the deal? Brazilian startup Ai Pathology TechDealroom has a profile for this one. Try Dealroom → has raised R$4 million (about $768,226) in a seed round led by family office EnseadaDealroom has a profile for this one. Try Dealroom →, founded by SulAmérica's founders. The Limeira-based company, founded in 2024, builds software that flags suspicious skin lesions from a smartphone photo and returns a risk classification within seconds.
The product: Its app, Nevo, runs on any handset with a camera, including low-cost devices, and claims a 93% accuracy rate. In Brazil, where skin cancer accounts for about 230,000 new cases a year, the founders aim to speed up first-line triage for patients who might otherwise wait months for specialist care.
Why now? The company has joined Nvidia's Inception programme, which provides compute, training, and mentoring, and is part of Harvard Innovation Labs. The seed capital will help it navigate regulation as it awaits approval from Anvisa, which began overseeing AI medical software in 2024.
What's the endgame? Ai Pathology has assembled about 90,000 images through partnerships across Brazil and plans to grow that archive to 4 million, aiming to build one of the world's largest dermatology datasets. Chief executive Willian Boelcke said Brazil's wide range of skin tones could become an advantage, producing a model "useful well beyond the domestic market." If Anvisa approval comes through, the company plans to raise about $8 million in Series A funding and pursue clinical studies in the US and a future FDA submission.
Early traction: Its first major use case, with Senar in Goiás, screened 2,058 rural workers, flagged around 10% as priority cases, and detected 75 early-stage skin cancers referred for urgent treatment. In Brazil, the commercial model is already B2B: NaturaDealroom has a profile for this one. Try Dealroom → offers the technology to its roughly 8,000 employees, and the Sabin laboratory group in Brasília has signed up.
What could go wrong? Commercialisation hinges on Anvisa clearance, and the planned US expansion would require an FDA submission — a longer, costlier path.
The signal: The round is modest by medtech standards, but it lands amid a surge in AI skin-cancer detection funding. Peers like DermaSensor raised $16 million in 2025 and the UK's Skin Analytics secured £15 million, signalling the category is shifting from pilots toward regulated commercialisation.
Read more: Noah News
Image credit: Generated with Gemini
